|Last Price$4.55||Day Change (%)0%|
|Open Price$4.57||Day Change ($)0.00|
|Day Range4.53–4.61||52-Week Range4.19–6.95|
As of Fri 05/17/2013 06:23 PM EDT | USD
Good day, ladies and gentlemen, and welcome to the Second Quarter 2011 Exelixis Financial Results Conference Call. My name is Ann, and I will be your coordinator for today's call. As a reminder, this conference is being recorded for replay purposes. At this time, all participants are in a ...
Lack of competitive advantages may mean these companies aren't the bargains they seem to be.
We see opportunity as fleeing investors trigger an irrational sell-off.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
2011 was a relatively light year for biotech M&A, but it looks like activity is picking up in 2012.
The five biotech ETFs have very different portfolios with markedly different performance.
Health-care analyst Lauren Migliore looks at what makes a biotech firm a likely takeout candidate and reveals our top five biotech M&A picks for 2010.
M&A activity grew in 2010, and we expect deal volume to remain strong in 2011.